EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs : vimarsana.com

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.

Related Keywords

Amsterdam , Noord Holland , Netherlands , Charlottelm Krieckaert , , American College Of Rheumatology , Immunology Center , Amsterdam Rheumatology ,